AI-Driven Public Health + Instant Results = Explosive Growth
Artificial intelligence isn’t just the future - it’s here, transforming industries like medical equipment and healthcare. From AI-driven software that predicts bacterial outbreaks to breakthroughs in infection control, this technology is set to tackle some of the world’s most pressing health challenges.
According to PwC, AI could generate a staggering $15 TRILLION in new wealth by 2030.
That's:
.png)
“Our single largest investment is in advancing AI.” – Mark Zuckerberg
“AI is every bit as important as the PC or the internet.” – Bill Gates
“AI can change everything in the world.” – Warren Buffett
So, how do you get your cut of this $15 trillion tidal wave?
Well, one little-known stock just raised $18M and went public this year with a modest $120M market cap - while tackling a MASSIVE global challenge.
If you’re ready to learn more about this disruptive AI stock, keep reading below.
Imagine your child is suffering from a severe sore throat, and you know that if it's strep throat, immediate antibiotics are crucial. Now, think about the heartbreaking reality in developing countries, where Strep A claims countless lives. The World Health Organization estimates that 600 million people contract strep throat each year, and tragically, the infection kills 500,000 people annually. Yet, this urgent crisis often goes unnoticed and underreported.
What if a company could develop a Strep A test that is 97% accurate (and rising) that anyone could administer using just a mobile app that tells you in less than one minute whether antibiotics are required?
Well, one company has:
LIGHT AI - Stock Symbol: $ALGO.NEO
How Did Light AI Create This?
Light AI has developed an AI model that gets smarter everyday as its image database from scans of patients’ throats grows. With 60,000 images in its image database currently, Light AI’s technology can determine whether a patient has strep throat with 97% accuracy. Light AI also has a proprietary cloud-based library of 300,000 images.
Regarding Light AI’s technology, keep this in mind: getting to this point required enormous amounts of time (eight years of development), persistence (13 partners helped to get the company to this stage), and investment dollars ($18 million to date). These factors combine to create a huge barrier to entry for potential competitors.
How Testing for Strep A Has Been Performed for Years
.png)
How Light AI’s Testing Works
.png)
An Additional Positive Related to Light AI’s Approach
Only 20%-30% of U.S. patients complaining of a sore throat who visit a physician for treatment actually have a bacterial infection which requires antibiotics. However, physicians prescribe antibiotics for 60% of these patients, making most of these doctor visits unnecessary.
The real impact of a patient’s taking antibiotics for a malady that does not require them is not just wastefulness. The more nefarious and cumulative impact of such action is antimicrobial resistance, a phenomenon which occurs when bacteria or virus become resistant to the effects of antimicrobials such as antibiotics. The World Health Organization consistently ranks Antimicrobial Resistance as one of the top 5 global health threats.
Does the Management Team at Light AI Have Experience in Commercializing a Medical Device?
Yes, indeed.
Peter Whitehead, Light AI’s Founder and CEO, is the inventor of VELScope, a handheld device that dentists use to help detect oral cancer and other abnormalities in the mouth. VELScope has been used in over 50 million oral health examinations by 10,000+ dental clinics in 23 countries. Peter has also founded multiple AI/Machine Learning companies.
How Will Light AI Bring This Breakthrough Technology to the Market?
Lower Middle Income Countries Via a Partnership with TC4A
Wellness Direct-to-Consumer
FDA Commercialization
4 Top Reasons to Watch $ALGO
Newly listed on the CBOE/NEO Canada Exchange (symbol: ALGO), Light AI Inc. is set to launch its disruptive AI-powered app in 2025, which will turn smartphones into powerful tools for rapid test disease detection — a market forecasted to exceed US$30 billion by 2030.
Starting with a focus on Group A Streptococcus (“GAS” or “Strep A”), which infects over 600 million people annually worldwide, killing as many children as malaria, Light AI has developed multiple go-to-market strategies aligned with global efforts to combat antibiotic overuse and the rise of drug-resistant infections.
As the first-and-only AI-enabled mover in the massive rapid test market, Light AI’s patented, app-based solution provides highly accurate results in under a minute without the need for swabs, lab tests, or proprietary hardware. All you need is a smartphone, and the app will guide you through the process.
Supported by expert leadership and five granted patents, Light AI is poised for rapid scaling in the AI healthcare market, leveraging the global installed base of over 4 billion smartphones to bring smartphone diagnostics to the world, bringing a dramatic improvement to healthcare access globally.
Quick Links to Online Brokerages
Disclaimers
FORWARD-LOOKING STATEMENTS AND LEGAL DISCLAIMERS - PLEASE READ CAREFULLY
PAID ADVERTISEMENT
Senergy Communications Capital Inc. (DBA AI Capital News) (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Light AI Inc. made a one-time payment of CAD $100,000 to provide marketing services for a term of two months. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment.
Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
We are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.
Consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.
MARKET & INDUSTRY DATA
The information contained herein includes market and industry data that has been obtained from third party sources, including industry publications. The Company believes that its industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources. We have asked the Light AI management team to review and grant approval on the usage of this content.
FULL DISCLAIMER
Please read our full disclaimer & disclosure at https://senergy.capital/disclaimer.
Stay up to date and subscribe to our (100% free) newsletter
.png)